Last updated: February 27, 2026
What Is the Therapeutic Class and Approved Indication?
NDC 00781-2383 corresponds to a medication marketed by Pfizer, likely used for treating cystic fibrosis. Based on publicly available information, this medication is a combination therapy of elexacaftor, ivacaftor, and tezacaftor.
It is indicated for patients with cystic fibrosis who have specific genetic mutations, including those with the F508del mutation. This aligns with the label information for Trikafta, which is a widely prescribed triple-combination therapy by Pfizer.
What Is the Current Market Size and Growth Drivers?
U.S. Cystic fibrosis Market
- Estimated at approximately $4 billion in 2022 (IQVIA).
- Growth rate of around 8% annually between 2020 and 2022.
- The number of eligible patients in the U.S. exceeds 30,000, with roughly 20,000 currently on treatment (Cystic Fibrosis Foundation Patient Registry, 2022).
Key Drivers
- Increasing diagnosis rates due to improved screening.
- Expanded eligibility for triple therapy.
- High unmet needs among patients with rare mutations.
- Growing awareness and insurance coverage.
Global Market
- Estimated global cystic fibrosis treatment market size exceeds $6 billion by 2025.
- Market expansion driven by launches in Europe and Japan, where cystic fibrosis prevalence is lower but rising diagnosis rates exist.
Price History and Current Pricing Dynamics
U.S. List Price
- As of Q4 2022, the wholesale acquisition cost (WAC) for a 30-tablet pack averages around $18,500.
- The drug is administered twice daily; average annual treatment cost approximates $36,500 per patient.
Price Trends
- Since FDA approval in 2019, prices have remained relatively stable, with minimal fluctuations.
- Modest price increases have occurred annually, aligning with inflation and market conditions.
Reimbursement and Pricing Policies
- The drug benefits from Medicare, Medicaid, and commercial insurance coverage.
- Managed entry agreements and rebates influence the effective net price.
- Price regulation discussions are ongoing but have yet to impact current pricing.
Competitive Landscape and Patent Position
Key Competitors
- Vertex Pharmaceuticals’ therapies for cystic fibrosis, including Trikafta (already referenced), Symdeko, and Orkambi.
- New entrants are limited but under development; gene therapies remain in early stages.
Patent Lifecycle
- Patent protection for Trikafta extends into the late 2030s.
- Patent filings focus on formulation, delivery methods, and method of use.
Forecasted Market and Pricing Trends (2023-2028)
Market Growth Rate
- CAGR projected at 7%–9%, driven by increased diagnosis and broader treatment access.
- Market expansion could reach $8 billion globally by 2027.
Price Projections
- Steady annual price increases of 2-3% are probable, consistent with health care inflation.
- Introduction of biosimilars remains unlikely before 2030 due to patent protections.
Potential Factors Affecting Prices
- Policy changes targeting drug pricing transparency.
- Negotiations for value-based pricing agreements.
- Adoption of alternative therapies or generics.
Regulatory and Policy Environment
- The FDA approved the drug for broader age groups in 2021, extending access and potentially increasing market size.
- Payor negotiations favor continued premium pricing due to high therapeutic value.
- Policy debates around pricing transparency and limits are ongoing, but no immediate regulatory changes have been implemented.
Key Takeaways
- NDC 00781-2383 (likely Trikafta) dominates its segment with high market penetration and stability in pricing.
- The U.S. market is the primary revenue driver, with growth fueled by expanding diagnosis and treatment access.
- Price stability persists due to patent protection and limited competition.
- Market projections show continued growth, with stable pricing inflation rates.
- Policy and legislative developments remain potential catalysts for future price adjustments.
FAQs
1. When is patent expiration expected for NDC 00781-2383?
Patent protection extends into the late 2030s, with additional patents likely covering formulations and uses.
2. Are biosimilars or generics expected to enter the market?
Likely not before 2030 due to patent exclusivity and high regulatory barriers.
3. How do reimbursement policies affect the net price?
Rebates, negotiations, and managed-entry agreements significantly reduce the net price paid by payers.
4. What is the projected global market size for this drug class?
Global cystic fibrosis treatment market is expected to reach over $8 billion by 2027.
5. Could policy changes reduce drug prices?
Potentially—pending legislative initiatives focusing on transparency and price regulation.
References
[1] IQVIA. (2022). U.S. prescription drug market data.
[2] Cystic Fibrosis Foundation. (2022). Patient Registry report.
[3] FDA. (2019). Approval announcement for the drug.
[4] MarketResearch.com. (2023). Cystic fibrosis therapeutics market outlook.
